News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Esperion Therapeutics, Inc. (ESPR) Names Mark E. McGovern, M.D., FACC, FACP, Director


2/13/2014 10:01:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PLYMOUTH, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Mark E. McGovern, M.D., FACC, FACP, as a Director. Dr. McGovern will serve as a Class I director with a term of office expiring at the 2014 annual meeting of stockholders.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES